Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560423 | 1.00 | MAPT (0.54) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL560422 | 1.00 | MAPT (0.54) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL1396850 | 0.83 | MAPT (0.50) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL25962782 | 0.82 | KDM4E (0.43) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL30612980 | 0.81 | ACE (0.48) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL27400867 | 0.80 | SMN1; SMN2 (0.38) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL15745110 | 0.80 | KDM4E (0.38) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL10540962 | 0.80 | SMN1; SMN2 (0.38) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL19229970 | 0.80 | KDM4E (0.38) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL24513378 | 0.79 | KDM4E (0.47) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| CN-120202010-A | Ligand-oligonucleotide conjugates and linkers for use therewith | 上海京新生物医药有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2025-02-27 | — | — | US | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12214043-B2 | Therapeutic nanomaterials | UNIVERSITY OF CONNECTICUT | 2025-02-04 | — | — | US | disclosed |
| US-12173291-B2 | Unnatural base pair compositions and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-12-24 | — | — | US | disclosed |
| US-7560227-B2 | Biomarkers of vulnerable atherosclerotic plaques and methods of use | UNIVERSITY OF MASSACHUSETTS (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070207507-A1 | Biomarkers of vulnerable atherosclerotic plaques and methods of use | UNIVERSITY OF MASSACHUSETTS (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2006093973-A2 | BIOMARKERS OF VULNERABLE A THEROSCLEROTIC PLAQUES AND METHODS OF USE | UNIVERSITY OF MASSACHUSETTS (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2005100382-A1 | VERTEBRATE PEPTIDE MODULATORS OF LIPID METABOLISM | BLM GROUP, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050222040-A1 | Vertebrate peptide modulators of lipid metabolism | BLM GROUP, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-6890902-B2 | Cytotoxic modified lactoferrin peptides | ALPHARMA AS (NO) | 2005-05-10 | — | — | US | disclosed |
| US-20030022821-A1 | Bioactive peptides | ALPHARMA AS | 2003-01-30 | — | — | US | disclosed |
| US-5580953-A | USEFUL IN THERAPY OF TYPE 2 DIABETES MELLITUS, IMPAIRED GLUCOSE TOLERANCE, OBESITY AND INSULIN RESISTANCE | AMYLIN PHARMACEUTICALS, INC. (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0568687-A1 | NOVEL AMYLIN ANTAGONIST PEPTIDES AND USES THEREFOR | AMYLIN PHARMACEUTICALS, INC. (US) | 1993-11-10 | — | — | EP | disclosed |
| WO-1993010147-A1 | NOVEL AMYLIN ANTAGONIST PEPTIDES AND USES THEREFOR | AMYLIN PHARMACEUTICALS, INC. (US) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | MAPT 194/4885KDM4E 2272/4885THRB 2002/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | MAPT 1013/4885KDM4E 848/4885THRB 3982/4885 |
| US-20070207507-A1 | Biomarkers of vulnerable atherosclerotic plaques and methods of use | CD68, APOB, FABP3 | MAPT 3850/4885KDM4E 4167/4885THRB 3968/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | MAPT 605/4885KDM4E 2142/4885THRB 3115/4885 |
| US-12173291-B2 | Unnatural base pair compositions and methods of use | RNGTT, SPOUT1, NPEPPS | MAPT 3580/4885KDM4E 4046/4885THRB 2274/4885 |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | RNGTT, SPOUT1, NPEPPS | MAPT 3580/4885KDM4E 4046/4885THRB 2274/4885 |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | RNGTT, TRMT1, OSGEP | MAPT 3383/4885KDM4E 3826/4885THRB 1802/4885 |
| US-20030022821-A1 | Bioactive peptides | VIP, LITAF, LNPEP | MAPT 4597/4885KDM4E 4477/4885THRB 1687/4885 |
| US-12214043-B2 | Therapeutic nanomaterials | TIE1, TEKT1, POLRMT | MAPT 194/4885KDM4E 2272/4885THRB 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.